Prostate Cancer Diagnosis & Treatment Market
Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035
Industry Overview
Prostate cancer diagnosis & treatment market was valued at $21,428.00 million in 2025 and is projected to reach $51,381.41 million by 2035, growing at a CAGR of 9.2% during the forecast period (2026-2035). The market is growing due to the increasing incidence of prostate cancer, particularly among the aging male population. Rising awareness regarding early screening through prostate-specific antigen testing and digital rectal examination is contributing to higher diagnosis rates. Continuous advancements in diagnostic technologies and imaging accuracy are improving early detection and risk stratification. Expanding availability of advanced therapeutic options, including immunotherapy and targeted therapy, is enhancing treatment outcomes and patient survival. In addition, supportive reimbursement frameworks and strengthening oncology infrastructure across emerging and developed economies are reinforcing sustained market expansion.
Market Dynamics
Rising Disease Burden and Expanding Diagnostic Adoption
The rising incidence of prostate cancer, particularly among men above 60 years of age, remains a primary growth driver for the prostate cancer diagnosis and treatment market. Demographic shifts toward an aging population are directly increasing the patient pool requiring routine screening, confirmatory diagnostics, and long-term therapeutic management. Clinical guidelines in several countries recommend regular prostate-specific antigen testing and digital rectal examination for high-risk groups, supporting consistent diagnostic volumes. Improvements in laboratory accuracy, biomarker validation, and imaging integration are strengthening early-stage detection rates. Earlier diagnosis is leading to higher treatment initiation, thereby sustaining demand across hormonal therapy, radiation therapy, chemotherapy, immunotherapy, and targeted therapy segments.
Advancements in Therapeutic Innovation and Clinical Infrastructure
Continuous advancement in treatment innovation and precision oncology represents another major driver for market expansion. Pharmaceutical companies are expanding pipelines focused on next-generation hormonal agents, radioligand therapies, and immune-based approaches designed to improve survival outcomes in advanced and metastatic cases. Regulatory approvals for novel targeted therapies are broadening the available treatment landscape and encouraging earlier adoption in clinical practice. Expansion of specialized oncology centers and improved access to reimbursement in key healthcare systems are increasing therapy uptake. Growing clinical research activity and participation in oncology trials are accelerating the introduction of differentiated therapeutic options, reinforcing sustained market growth.
Market Segmentation
- Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
- Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.
Expanding Role of Biomarker-Based Screening
Tumor biomarker testing has emerged as the largest diagnostic sub-segment in prostate cancer detection, supported by the widespread use of PSA-based blood screening and other molecular assays. These tests account for roughly 38% of global diagnostic activity due to their non-invasive nature and ability to enable early identification of malignancies. Rising awareness programs and routine screening among aging male populations continue to expand test volumes worldwide. Companies such as Abbott, Roche, and Myriad Genetics are strengthening their positions through advanced biomarker panels and companion diagnostics. Recent developments focus on multiplex genomic assays and PSMA-based biomarkers that improve detection accuracy and support personalized treatment planning. Integration of AI-assisted imaging and biomarker analytics is further reshaping early-stage screening workflows across hospitals and diagnostic laboratories.
Breakthrough Momentum in Cancer Immunotherapy
Within treatment segments, immunotherapy represents the most rapidly expanding therapeutic approach for prostate cancer management. Growth is supported by increasing clinical adoption of immune checkpoint inhibitors and personalized cancer vaccines targeting advanced or resistant disease stages. Rising incidence of metastatic prostate cancer and the need for therapies with improved survival outcomes are accelerating investment in this segment. Pharmaceutical leaders, including Bristol Myers Squibb, Merck, and AstraZeneca, are advancing combination immunotherapy trials to improve patient response rates. Recent trends emphasize precision oncology strategies that combine immunotherapy with hormonal therapy or targeted agents to enhance efficacy. Continued regulatory approvals and ongoing clinical studies are expected to strengthen the role of immune-based treatments in next-generation prostate cancer care.
Regional Outlook
The global prostate cancer diagnostic and therapeutic market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Strong Innovation Landscape in North America
North America continues to lead the prostate cancer diagnosis and treatment market due to advanced healthcare infrastructure and strong adoption of early screening programs. The region accounts for nearly 40–45% of global market revenue, supported by widespread diagnostic testing and high treatment accessibility. Growing awareness regarding early prostate cancer detection and favorable reimbursement policies are encouraging the use of PSA testing and advanced therapeutic approaches. The United States remains the primary contributor with strong participation in clinical trials and oncology research. Major pharmaceutical companies, including Johnson & Johnson, Merck, and AbbVie, maintain a strong presence through innovative hormone therapies and targeted drugs.
Advancing Oncology Care Across Europe
Europe represents the second-largest regional market, supported by a growing elderly population and strong public healthcare systems. Countries such as Germany, France, and the United Kingdom contribute significantly through structured cancer screening programs and improved oncology infrastructure. Increasing government initiatives for early detection and expanding PSA testing coverage are improving diagnosis rates across the region. Around 60% of diagnostic consultations in Europe now involve PSA-based screening methods. Leading pharmaceutical companies, including Bayer, Astellas Pharma, Ipsen, and Sanofi, are actively strengthening their therapeutic portfolios with hormonal and targeted therapies.
Market Players Outlook
The major companies operating in the global prostate cancer diagnostic and therapeutic market include Johnson & Johnson, Astellas Pharma, Pfizer, Novartis, AstraZeneca, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In December 2025, Johnson & Johnson announced that the US Food and Drug Administration approved a supplemental New Drug Application for AKEEGA (niraparib and abiraterone acetate) in combination with prednisone for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer. The approval is supported by results from the Phase 3 AMPLITUDE study, which demonstrated a 54 percent reduction in the risk of radiographic progression or death compared to standard therapy.
- In June 2025, Telix Pharmaceuticals announced the US commercial launch of Gozellix, a next-generation PSMA PET imaging agent for prostate cancer. The product is indicated for the detection of PSMA-positive lesions in men with suspected metastasis or biochemical recurrence based on elevated PSA levels.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis – Diagnostic Techniques | Therapy ($ Million)
- Prostate Cancer Diagnostic and Therapeutic Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Prostate Cancer Diagnostic and Therapeutic Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Prostate Cancer Diagnostic and Therapeutic Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Prostate Cancer Diagnostic and Therapeutic Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Prostate Cancer Diagnostic and Therapeutic Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Prostate Cancer Diagnostic and Therapeutic Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Prostate Cancer Diagnostic and Therapeutic Market Revenue and Share by Manufacturers
- prostate cancer diagnostic and therapeutic Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Astellas Pharma
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AstraZeneca
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Johnson & Johnson
- Key Company Analysis
- Global Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis by Diagnostic Techniques ($ Million)
- Prostate Specific Antigen Test
- Digital Rectal Exam
- Global Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis by Therapy ($ Million)
- Hormonal Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Targeted Therapy
- Regional Analysis
- North American Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis – Diagnostic Techniques | Therapy | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis – Diagnostic Techniques | Therapy | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis – Diagnostic Techniques | Therapy | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Prostate Cancer Diagnostic and Therapeutic Market Sales Analysis – Diagnostic Techniques | Therapy | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bracco Imaging
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Clovis Oncology
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Curium
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eisai
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Exact Sciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GE HealthCare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hologic
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lantheus Holdings
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Myriad Genetics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche Diagnostics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Siemens Healthineers
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Telix Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Diagnostic Techniques, 2026–2035 ($ Million)
2. Global Prostate Specific Antigen Test (Psa) Market Research And Analysis By Region, 2026–2035 ($ Million)
3. Global Digital Rectal Exam (Dre) Market Research And Analysis By Region, 2026–2035 ($ Million)
4. Global Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Therapy, 2026–2035 ($ Million)
5. Global Hormonal Therapy For Prostate Cancer Market Research And Analysis By Region, 2026–2035 ($ Million)
6. Global Chemotherapy For Prostate Cancer Market Research And Analysis By Region, 2026–2035 ($ Million)
7. Global Immunotherapy For Prostate Cancer Market Research And Analysis By Region, 2026–2035 ($ Million)
8. Global Radiation Therapy For Prostate Cancer Market Research And Analysis By Region, 2026–2035 ($ Million)
9. Global Targeted Therapy For Prostate Cancer Market Research And Analysis By Region, 2026–2035 ($ Million)
10. Global Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Region, 2026–2035 ($ Million)
11. North American Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Country, 2026–2035 ($ Million)
12. North American Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Diagnostic Techniques, 2026–2035 ($ Million)
13. North American Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Therapy, 2026–2035 ($ Million)
14. European Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Country, 2026–2035 ($ Million)
15. European Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Diagnostic Techniques, 2026–2035 ($ Million)
16. European Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Therapy, 2026–2035 ($ Million)
17. Asia-Pacific Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Country, 2026–2035 ($ Million)
18. Asia-Pacific Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Diagnostic Techniques, 2026–2035 ($ Million)
19. Asia-Pacific Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Therapy, 2026–2035 ($ Million)
20. Rest Of The World Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Region, 2026–2035 ($ Million)
21. Rest Of The World Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Diagnostic Techniques, 2026–2035 ($ Million)
22. Rest Of The World Prostate Cancer Diagnosis & Treatment Market Research And Analysis By Therapy, 2026–2035 ($ Million)
1. Global Prostate Cancer Diagnosis & Treatment Market Share by Diagnostic Technique, 2026 vs 2035 (%)
2. Global Prostate Specific Antigen Test (PSA) Market Share by Region, 2026 vs 2035 (%)
3. Global Digital Rectal Exam (DRE) Market Share by Region, 2026 vs 2035 (%)
4. Global Prostate Cancer Diagnosis & Treatment Market Share by Therapy, 2026 vs 2035 (%)
5. Global Hormonal Therapy for Prostate Cancer Market Share by Region, 2026 vs 2035 (%)
6. Global Chemotherapy for Prostate Cancer Market Share by Region, 2026 vs 2035 (%)
7. Global Immunotherapy for Prostate Cancer Market Share by Region, 2026 vs 2035 (%)
8. Global Radiation Therapy for Prostate Cancer Market Share by Region, 2026 vs 2035 (%)
9. Global Targeted Therapy for Prostate Cancer Market Share by Region, 2026 vs 2035 (%)
10. Global Prostate Cancer Diagnosis & Treatment Market Share by Region, 2026 vs 2035 (%)
11. US Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
12. Canada Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
13. UK Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
14. France Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
15. Germany Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
16. Italy Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
17. Spain Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
18. Rest of Europe Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
19. China Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
20. Japan Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
21. India Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
22. South Korea Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
23. Australia and New Zealand Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
24. ASEAN Economies Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
25. Rest of Asia-Pacific Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
26. Latin America Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
27. Middle East and Africa Prostate Cancer Diagnosis & Treatment Market Size, 2026–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
